Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

Management of locally recurrent nasopharyngeal carcinoma.

Lee AWM, Ng WT, Chan JYW, Corry J, Mäkitie A, Mendenhall WM, Rinaldo A, Rodrigo JP, Saba NF, Strojan P, Suárez C, Vermorken JB, Yom SS, Ferlito A.

Cancer Treat Rev. 2019 Sep;79:101890. doi: 10.1016/j.ctrv.2019.101890. Epub 2019 Aug 21. Review.

PMID:
31470314
2.

Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation.

Pan C, Chun J, Li D, Boese AC, Li J, Kang J, Umano A, Jiang Y, Song L, Magliocca KR, Chen ZG, Saba NF, Shin DM, Owonikoko TK, Lonial S, Jin L, Kang S.

J Clin Invest. 2019 Aug 26. pii: 125963. doi: 10.1172/JCI125963. [Epub ahead of print]

3.

Small cell and large cell neuroendocrine carcinoma of the larynx: A comparative analysis.

Strojan P, Hernandez-Prera JC, Beitler JJ, Eisbruch A, Saba NF, Mendenhall WM, Nieto CS, Smee R, Rinaldo A, Ferlito A.

Cancer Treat Rev. 2019 Aug;78:42-51. doi: 10.1016/j.ctrv.2019.08.002. Epub 2019 Aug 8.

PMID:
31437725
4.

Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age.

Saba NF, Blumenschein G Jr, Guigay J, Licitra L, Fayette J, Harrington KJ, Kiyota N, Gillison ML, Ferris RL, Jayaprakash V, Li L, Brossart P.

Oral Oncol. 2019 Sep;96:7-14. doi: 10.1016/j.oraloncology.2019.06.017. Epub 2019 Jul 3.

5.

Small Cell and Squamous Cell Carcinomas of the Head and Neck: Comparing Incidence and Survival Trends Based on Surveillance, Epidemiology, and End Results (SEER) Data.

Bean MB, Liu Y, Jiang R, Steuer CE, Patel M, McDonald MW, Higgins KA, Beitler JJ, Shin DM, Saba NF.

Oncologist. 2019 Aug 7. pii: theoncologist.2018-0054. doi: 10.1634/theoncologist.2018-0054. [Epub ahead of print]

PMID:
31391295
6.

Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial.

Adkins D, Ley J, Neupane P, Worden F, Sacco AG, Palka K, Grilley-Olson JE, Maggiore R, Salama NN, Trinkaus K, Van Tine BA, Steuer CE, Saba NF, Oppelt P.

Lancet Oncol. 2019 Sep;20(9):1295-1305. doi: 10.1016/S1470-2045(19)30405-X. Epub 2019 Jul 24.

PMID:
31351869
7.

Survival Outcomes With Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer: A Propensity Score-Matched Analysis of the National Cancer Database.

Tian S, Zhang X, Jiang R, Pillai RN, Owonikoko TK, Steuer CE, Saba NF, Pakkala S, Patel PR, Belani CP, Khuri FR, Curran WJ, Ramalingam SS, Behera M, Higgins KA.

Clin Lung Cancer. 2019 Jun 18. pii: S1525-7304(19)30156-1. doi: 10.1016/j.cllc.2019.06.014. [Epub ahead of print]

PMID:
31296433
8.

Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.

Haddad R, Concha-Benavente F, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Kasper S, Vokes EE, Worden F, Saba NF, Tahara M, Jayaprakash V, Lynch M, Li L, Gillison ML, Harrington KJ, Ferris RL.

Cancer. 2019 Sep 15;125(18):3208-3218. doi: 10.1002/cncr.32190. Epub 2019 Jun 27.

9.

Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.

Ferris RL, Licitra L, Fayette J, Even C, Blumenschein G Jr, Harrington KJ, Guigay J, Vokes EE, Saba NF, Haddad R, Ramkumar S, Russell J, Brossart P, Tahara M, Colevas AD, Concha-Benavente F, Lynch M, Li L, Gillison ML.

Clin Cancer Res. 2019 Sep 1;25(17):5221-5230. doi: 10.1158/1078-0432.CCR-18-3944. Epub 2019 Jun 25.

PMID:
31239321
10.

Racial Disparities, Outcomes, and Surgical Utilization among Hispanics with Esophageal Cancer: A Surveillance, Epidemiology, and End Results Program Database Analysis.

Gupta DR, Liu Y, Jiang R, Walid S, Higgins K, Landry J, McDonald M, Willingham FF, El-Rayes BF, Saba NF.

Oncology. 2019;97(1):49-58. doi: 10.1159/000499716. Epub 2019 May 20.

PMID:
31108497
11.

Locally advanced high-risk HPV related oropharyngeal squamous cell carcinoma (OPSCC); have we forgotten it is a different disease?

Saba NF, Li S, Hussain ZA, Subramanian R, Califano JA, Chung CH.

Cancers Head Neck. 2018 Oct 3;3:8. doi: 10.1186/s41199-018-0035-7. eCollection 2018.

12.

Inositol-triphosphate 3-kinase B confers cisplatin resistance by regulating NOX4-dependent redox balance.

Pan C, Jin L, Wang X, Li Y, Chun J, Boese AC, Li D, Kang HB, Zhang G, Zhou L, Chen GZ, Saba NF, Shin DM, Magliocca KR, Owonikoko TK, Mao H, Lonial S, Kang S.

J Clin Invest. 2019 May 13;129(6):2431-2445. doi: 10.1172/JCI124550. eCollection 2019 May 13.

13.

Prognostic value of radiographically defined extranodal extension in human papillomavirus-associated locally advanced oropharyngeal carcinoma.

Tian S, Ferris MJ, Switchenko JM, Magliocca KR, Cassidy RJ, Jhaveri J, Aiken AH, Baugnon KL, Hudgins PA, Kendi ATK, Patel MR, Saba NF, Curran WJ, Beitler JJ.

Head Neck. 2019 Sep;41(9):3056-3063. doi: 10.1002/hed.25791. Epub 2019 May 2.

PMID:
31046181
14.

T4 Laryngeal Cancer With Good Function: Should We Be Reluctant to Treat Without Surgery?

Beitler JJ, Ridge JA, Vermorken JB, Bradford CR, Strojan P, Saba NF, Suárez C, Rodrigo JP, Rinaldo A, Chen AY, Ferlito A.

Int J Radiat Oncol Biol Phys. 2018 Dec 1;102(5):1400-1403. doi: 10.1016/j.ijrobp.2018.03.007. No abstract available.

PMID:
31014779
15.

Prognostic and predictive factors in recurrent and/or metastatic head and neck squamous cell carcinoma: A review of the literature.

Bossi P, Alfieri S, Strojan P, Takes RP, López F, Mäkitie A, Saba NF, Rodrigo JP, Bradford C, Suarez C, Zafereo M, Forastiere AA, Vermorken JB, Quer M, Sanabria A, Simo R, de Bree R, Rinaldo A, Ferlito A.

Crit Rev Oncol Hematol. 2019 May;137:84-91. doi: 10.1016/j.critrevonc.2019.01.018. Epub 2019 Feb 13. Review.

PMID:
31014517
16.

Survival outcomes by high-risk human papillomavirus status in nonoropharyngeal head and neck squamous cell carcinomas: A propensity-scored analysis of the National Cancer Data Base.

Tian S, Switchenko JM, Jhaveri J, Cassidy RJ, Ferris MJ, Press RH, Pfister NT, Patel MR, Saba NF, McDonald MW, Higgins KA, Yu DS, Curran WJ, Gillespie TW, Beitler JJ.

Cancer. 2019 Aug 15;125(16):2782-2793. doi: 10.1002/cncr.32115. Epub 2019 Apr 23.

PMID:
31012957
17.

Soy Isoflavone Supplementation Increases Long Interspersed Nucleotide Element-1 (LINE-1) Methylation in Head and Neck Squamous Cell Carcinoma.

Rozek LS, Virani S, Bellile EL, Taylor JMG, Sartor MA, Zarins KR, Virani A, Cote C, Worden FP, Mark MEP, McLean SA, Duffy SA, Yoo GH, Saba NF, Shin DM, Kucuk O, Wolf GT.

Nutr Cancer. 2019;71(5):772-780. doi: 10.1080/01635581.2019.1577981. Epub 2019 Mar 12.

PMID:
30862188
18.

Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis.

Mohamed A, Twardy B, Zordok MA, Ashraf K, Alkhoder A, Schrapp K, Steuer C, Chen Z, Pakkala S, Pillai R, Trad Wadsworth J, Higgins K, Beitler JJ, Ramalingam SS, Owonikoko TK, Khuri FR, Shin DM, Behera M, Saba NF.

Head Neck. 2019 May;41(5):1490-1498. doi: 10.1002/hed.25379. Epub 2019 Mar 5. Review.

PMID:
30835900
19.

Phase IB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy, Carboplatin, and Everolimus in Patients With Locally Advanced Esophageal Cancer.

Saba NF, Force S, Staley C, Fernandez F, Willingham F, Pickens A, Cardona K, Chen Z, Goff L, Cardin D, Lambright E, Nesbitt J, Krasinskas A, Higgins K, Harvey RD, Owonikoko T, Ramalingam SS, Shin DM, Beitler JJ, El-Rayes BF, Salaria S, El-Rifai W, Landry J, Chakravarthy AB.

Am J Clin Oncol. 2019 Apr;42(4):331-336. doi: 10.1097/COC.0000000000000524.

PMID:
30789414
20.

Prognostic implications of peritumoral vasculature in head and neck cancer.

Evans M, Baddour HM Jr, Magliocca KR, Müller S, Nannapaneni S, Chen AY, Kim S, Chen Z, Shin DM, Wang AY, Saba NF, Chen ZG.

Cancer Med. 2019 Jan;8(1):147-154. doi: 10.1002/cam4.1910. Epub 2018 Dec 21.

21.

Smoking, age, nodal disease, T stage, p16 status, and risk of distant metastases in patients with squamous cell cancer of the oropharynx.

Beitler JJ, Switchenko JM, Dignam JJ, McDonald MW, Saba NF, Shin DM, Magliocca KR, Cassidy RJ, El-Deiry MW, Patel MR, Steuer CE, Xiao C, Hudgins PA, Aiken AH, Curran WJ Jr, Le QT.

Cancer. 2019 Mar 1;125(5):704-711. doi: 10.1002/cncr.31820. Epub 2018 Dec 11.

PMID:
30548235
22.

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.

Siu LL, Even C, Mesía R, Remenar E, Daste A, Delord JP, Krauss J, Saba NF, Nabell L, Ready NE, Braña I, Kotecki N, Zandberg DP, Gilbert J, Mehanna H, Bonomi M, Jarkowski A, Melillo G, Armstrong JM, Wildsmith S, Fayette J.

JAMA Oncol. 2019 Feb 1;5(2):195-203. doi: 10.1001/jamaoncol.2018.4628.

PMID:
30383184
23.

Incidence of Cancer Treatment-Induced Arrhythmia Associated With Novel Targeted Chemotherapeutic Agents.

Nickel AC, Patel A, Saba NF, Leon AR, El-Chami MF, Merchant FM.

J Am Heart Assoc. 2018 Oct 16;7(20):e010101. doi: 10.1161/JAHA.118.010101.

24.

Salvage surgery for squamous cell carcinoma of the head and neck in the era of immunotherapy: Is it time to clarify our guidelines?

Saba NF, Mendenhall WM, Hutcheson K, Suárez C, Wolf G, Ferlito A.

Cancer. 2018 Nov 1;124(21):4163-4164. doi: 10.1002/cncr.31717. Epub 2018 Oct 5. No abstract available.

PMID:
30289965
25.

Deformable Registration of Histological Cancer Margins to Gross Hyperspectral Images using Demons.

Halicek M, Little JV, Wang X, Chen ZG, Patel M, Griffith CC, El-Deiry MW, Saba NF, Chen AY, Fei B.

Proc SPIE Int Soc Opt Eng. 2018 Feb;10581. pii: 105810N. doi: 10.1117/12.2293165. Epub 2018 Mar 6.

26.

Differential regulation of NF-kB and IRF target genes as they relate to fatigue in patients with head and neck cancer.

Xiao C, Beitler JJ, Higgins KA, Wommack EC, Saba NF, Shin DM, Bruner DW, Miller AH, Cole S.

Brain Behav Immun. 2018 Nov;74:291-295. doi: 10.1016/j.bbi.2018.09.013. Epub 2018 Sep 11.

PMID:
30217537
27.

Disparities in Postoperative Therapy for Salivary Gland Adenoid Cystic Carcinomas.

Cassidy RJ, Switchenko JM, El-Deiry MW, Belcher RH, Zhong J, Steuer CE, Saba NF, McDonald MW, Yu DS, Gillespie TW, Beitler JJ.

Laryngoscope. 2019 Feb;129(2):377-386. doi: 10.1002/lary.27302. Epub 2018 Sep 8.

PMID:
30194768
28.

Interleukin-6/STAT3 Signaling is Prominent and Associated with Reduced Overall Survival in p16 Negative Oropharyngeal Squamous Cell Carcinoma.

Lesinski GB, Nannapaneni S, Griffith CC, Patel M, Chen W, Chen Z, Ahmed R, Wieland A, Shin DM, Chen ZG, Saba NF.

Head Neck Pathol. 2019 Sep;13(3):304-312. doi: 10.1007/s12105-018-0962-y. Epub 2018 Sep 6.

29.

The Current Role of Salvage Surgery in Recurrent Head and Neck Squamous Cell Carcinoma.

Hamoir M, Schmitz S, Suarez C, Strojan P, Hutcheson KA, Rodrigo JP, Mendenhall WM, Simo R, Saba NF, D'Cruz AK, Haigentz M Jr, Bradford CR, Genden EM, Rinaldo A, Ferlito A.

Cancers (Basel). 2018 Aug 10;10(8). pii: E267. doi: 10.3390/cancers10080267. Review.

30.

MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation.

Jin L, Chun J, Pan C, Li D, Lin R, Alesi GN, Wang X, Kang HB, Song L, Wang D, Zhang G, Fan J, Boggon TJ, Zhou L, Kowalski J, Qu CK, Steuer CE, Chen GZ, Saba NF, Boise LH, Owonikoko TK, Khuri FR, Magliocca KR, Shin DM, Lonial S, Kang S.

Cancer Cell. 2018 Aug 13;34(2):315-330.e7. doi: 10.1016/j.ccell.2018.06.012. Epub 2018 Jul 19.

31.

Time to Rethink Our Strategy With a Preoperative Intensification Approach.

Saba NF.

Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):762. doi: 10.1016/j.ijrobp.2018.03.050. Epub 2018 Jun 20. No abstract available.

PMID:
29976483
32.

Radiographic Imaging Does Not Reliably Predict Macroscopic Extranodal Extension in Human Papilloma Virus-Associated Oropharyngeal Cancer.

Patel MR, Hudgins PA, Beitler JJ, Magliocca KR, Griffith CC, Liu Y, Bougnon K, El-Deiry M, Saba NF, Aiken AH.

ORL J Otorhinolaryngol Relat Spec. 2018;80(2):85-95. doi: 10.1159/000487239. Epub 2018 Jul 3.

PMID:
29969771
33.

Prognosis of subglottic carcinoma: Is it really worse?

Coskun H, Mendenhall WM, Rinaldo A, Rodrigo JP, Suárez C, Strojan P, López F, Mondin V, Saba NF, Shaha AR, Smee R, Takes RP, Ferlito A.

Head Neck. 2019 Feb;41(2):511-521. doi: 10.1002/hed.25172. Epub 2018 Jun 26. Review.

PMID:
29947111
34.

Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.

Ferris RL, Saba NF, Gitlitz BJ, Haddad R, Sukari A, Neupane P, Morris JC, Misiukiewicz K, Bauman JE, Fenton M, Jimeno A, Adkins DR, Schneider CJ, Sacco AG, Shirai K, Bowles DW, Gibson M, Nwizu T, Gottardo R, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM, Cohen EEW.

JAMA Oncol. 2018 Nov 1;4(11):1583-1588. doi: 10.1001/jamaoncol.2018.1888.

35.

Systemic therapy in non-conventional cancers of the larynx.

Tan E, Mody MD, Saba NF.

Oral Oncol. 2018 Jul;82:61-68. doi: 10.1016/j.oraloncology.2018.05.005. Epub 2018 May 26. Review.

PMID:
29909903
36.

Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.

Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML.

Oral Oncol. 2018 Jun;81:45-51. doi: 10.1016/j.oraloncology.2018.04.008. Epub 2018 Apr 17.

37.

CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.

Gillison ML, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Li L, Ferris RL.

Oncologist. 2018 Sep;23(9):1079-1082. doi: 10.1634/theoncologist.2017-0674. Epub 2018 Jun 4.

38.

Associations among human papillomavirus, inflammation, and fatigue in patients with head and neck cancer.

Xiao C, Beitler JJ, Higgins KA, Glazer T, Huynh LK, Paul S, Felger JC, Wommack EC, Saba NF, Shin DM, Bruner DW, Miller AH.

Cancer. 2018 Aug 1;124(15):3163-3170. doi: 10.1002/cncr.31537. Epub 2018 May 9.

39.

A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma.

Steuer CE, Griffith CC, Nannapaneni S, Patel MR, Liu Y, Magliocca KR, El-Deiry MW, Cohen C, Owonikoko TK, Shin DM, Chen ZG, Saba NF.

Mol Cancer Ther. 2018 Mar;17(3):710-716. doi: 10.1158/1535-7163.MCT-17-0504. Epub 2018 Feb 13.

40.

A Review of Photodynamic Therapy for Neoplasms of the Head and Neck.

Civantos FJ, Karakullukcu B, Biel M, Silver CE, Rinaldo A, Saba NF, Takes RP, Vander Poorten V, Ferlito A.

Adv Ther. 2018 Mar;35(3):324-340. doi: 10.1007/s12325-018-0659-3. Epub 2018 Feb 7. Review.

PMID:
29417455
41.

Head and Neck Cancer: A Review of the Impact of Treatment Delay on Outcome.

Coca-Pelaz A, Takes RP, Hutcheson K, Saba NF, Haigentz M Jr, Bradford CR, de Bree R, Strojan P, Lund VJ, Mendenhall WM, Nixon IJ, Quer M, Rinaldo A, Ferlito A.

Adv Ther. 2018 Feb;35(2):153-160. doi: 10.1007/s12325-018-0663-7. Epub 2018 Feb 2. Review.

PMID:
29396681
42.

Honokiol Radiosensitizes Squamous Cell Carcinoma of the Head and Neck by Downregulation of Survivin.

Wang X, Beitler JJ, Huang W, Chen G, Qian G, Magliocca K, Patel MR, Chen AY, Zhang J, Nannapaneni S, Kim S, Chen Z, Deng X, Saba NF, Chen ZG, Arbiser JL, Shin DM.

Clin Cancer Res. 2018 Feb 15;24(4):858-869. doi: 10.1158/1078-0432.CCR-17-0345. Epub 2017 Nov 27.

43.

Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma.

Zhang H, Kim S, Chen Z, Nannapaneni S, Chen AY, Moore CE, Sica G, Mosunjac M, Nguyen MLT, D'Souza G, Carey TE, Peterson LA, McHugh JB, Graham M, Komarck CM, Wolf GT, Walline HM, Bellile E, Riddell J 4th, Pai SI, Sidransky D, Westra WH, William WN Jr, Lee JJ, El-Naggar AK, Ferris RL, Seethala R, Grandis JR, Chen ZG, Saba NF, Shin DM; Head and Neck Cancer SPORE HIV supplement consortium.

Head Neck. 2017 Dec;39(12):2433-2443. doi: 10.1002/hed.24911. Epub 2017 Sep 25.

44.

Head and neck PET/CT therapy response interpretation criteria (Hopkins criteria) - external validation study.

Kendi AT, Brandon D, Switchenko J, Wadsworth JT, El-Deiry MW, Saba NF, Schuster DM, Subramaniam RM.

Am J Nucl Med Mol Imaging. 2017 Sep 1;7(4):174-180. eCollection 2017.

45.

Refining the predictors of outcome in patients with resectable esophageal cancer.

Saba NF.

Cancer. 2017 Nov 1;123(21):4097-4098. doi: 10.1002/cncr.30952. Epub 2017 Sep 8. No abstract available.

46.

The Impact of Histologic Phenotype in the Treatment of Sinonasal Cancer.

López F, Lund VJ, Suárez C, Snyderman CH, Saba NF, Robbins KT, Vander Poorten V, Strojan P, Mendenhall WM, Rinaldo A, Ferlito A.

Adv Ther. 2017 Oct;34(10):2181-2198. doi: 10.1007/s12325-017-0605-9. Epub 2017 Sep 4. Review.

PMID:
28871554
47.

Adenosquamous Carcinoma of the Esophagus: An NCDB-Based Investigation on Comparative Features and Overall Survival in a Rare Tumor.

Evans M, Liu Y, Chen C, Steuer C, Cassidy R III, Landry J, Higgins K, Beitler JJ, Willingham F, Owonikoko TK, Ramalingam SS, Shin DM, Jegadeesh NK, El-Rayes B, Fernandez F, Krasinskas AM, Gillespie T, Saba NF.

Oncology. 2017;93(5):336-342. doi: 10.1159/000466699. Epub 2017 Aug 24.

PMID:
28848104
48.

Resilience and biomarkers of health risk in Black smokers and nonsmokers.

Berg CJ, Haardörfer R, McBride CM, Kilaru V, Ressler KJ, Wingo AP, Saba NF, Payne JB, Smith A.

Health Psychol. 2017 Nov;36(11):1047-1058. doi: 10.1037/hea0000540. Epub 2017 Aug 21.

49.

Response assessment after induction chemotherapy for head and neck squamous cell carcinoma: From physical examination to modern imaging techniques and beyond.

de Bree R, Wolf GT, de Keizer B, Nixon IJ, Hartl DM, Forastiere AA, Haigentz M Jr, Rinaldo A, Rodrigo JP, Saba NF, Suárez C, Vermorken JB, Ferlito A.

Head Neck. 2017 Nov;39(11):2329-2349. doi: 10.1002/hed.24883. Epub 2017 Aug 17. Review.

50.

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.

Harrington KJ, Ferris RL, Blumenschein G Jr, Colevas AD, Fayette J, Licitra L, Kasper S, Even C, Vokes EE, Worden F, Saba NF, Kiyota N, Haddad R, Tahara M, Grünwald V, Shaw JW, Monga M, Lynch M, Taylor F, DeRosa M, Morrissey L, Cocks K, Gillison ML, Guigay J.

Lancet Oncol. 2017 Aug;18(8):1104-1115. doi: 10.1016/S1470-2045(17)30421-7. Epub 2017 Jun 23.

Supplemental Content

Support Center